In a significant pivot for Alzheimer’s research, scientists at the University of Kentucky have uncovered an unexpected mechanism behind the profound sleep disturbances that plague millions of patients. The study, published in the journal Alzheimer’s & Dementia, suggests that the cognitive decline and nocturnal restlessness associated with the disease may not be caused solely by the buildup of toxic proteins, but by an overzealous immune response within the brain itself. Most remarkably, researchers have demonstrated in animal models that these sleep disruptions can be reversed without the need to clear the amyloid plaques that have historically been the primary target of Alzheimer’s therapies.
Led by Shannon L. Macauley, Ph.D., an associate professor of physiology at the University of Kentucky College of Medicine, and first author Nicholas J. Constantino, Ph.D., the research team identified the brain’s own immune cells—microglia—as the primary culprits in disrupting healthy sleep cycles. For years, the scientific community has operated under the assumption that sleep loss in Alzheimer’s was a byproduct of neuronal damage or the physical accumulation of amyloid plaques. This new "paradigm-shifting" discovery suggests that the immune system’s reaction to these plaques creates a secondary, and perhaps more immediate, disruption to brain health.
How the Brain’s Immune System Disrupts Sleep
To visualize the mechanism, researchers offer a compelling analogy: imagine a small grease fire breaking out in a kitchen. Under normal circumstances, a fire suppression system would isolate the blaze. However, in the case of Alzheimer’s, the brain’s response is akin to a sprinkler system activating throughout the entire house, causing massive water damage in rooms where there was never a fire to begin with.
Microglia are the brain’s primary defense mechanism, tasked with cleaning up cellular debris and responding to injuries. However, when these cells detect amyloid plaques—the sticky, protein-rich deposits characteristic of Alzheimer’s—they appear to enter a state of chronic, overactive defense. Instead of merely containing the plaques, they release inflammatory signals that effectively keep the brain in a state of high alert.
"Basically, we showed that it is not the plaques themselves, or solely dysfunctional neurons, that cause sleep loss but actually microglia," explained Dr. Macauley. "Microglia are immune cells that, when they respond to plaques, kick off this elaborate cascade of inflammation, as if the microglia are partying all night, and keeping the brain awake." This "whole-house response" suggests that the immune system’s inflammatory reaction is responsible for a substantial portion of the neurological disruption observed in the disease, creating a cycle of dysfunction that exacerbates the patient’s condition.
Tracking Sleep Changes Inside the Brain
The research team utilized a rigorous comparative study, observing two distinct groups of mice: one group genetically predisposed to develop amyloid plaques and a control group of "wild-type" mice undergoing typical aging. By examining these animals at six months—when plaques first emerge—and at 18 months, when the pathology is advanced, the researchers were able to isolate the effects of Alzheimer’s from the natural aging process.
To accurately track sleep stages, the team equipped the mice with sophisticated electroencephalography (EEG) and electromyography (EMG) recording devices. While EEG measured the rhythmic electrical activity of neurons to determine sleep states, EMG tracked muscle activity. By integrating these data, the researchers could pinpoint exactly how long the mice spent in various sleep stages. Furthermore, the team employed light-sheet microscopy, a cutting-edge imaging technique that renders biological tissue transparent. By bathing the tissue in thin layers of laser light, the researchers were able to construct three-dimensional maps of the brain, visualizing exactly where and how microglia interacted with amyloid plaques.
Scientists Temporarily Remove 87% of Brain Immune Cells
The most pivotal phase of the study involved testing whether microglia were the direct agents of sleep disruption. The team utilized a drug called Pexidartinib (PLX3397), an experimental cancer treatment capable of blocking the cellular signals microglia require to survive. When administered through the mice’s food for a period of 14 days, the drug successfully depleted approximately 87% of the brain’s microglia.
The results were immediate and startling. With the majority of these inflammatory immune cells removed, the mice regained more than two hours of sleep per day. The improvement was not just in the quantity of sleep but in the quality; the animals spent significantly more time in non-rapid eye movement (NREM) sleep—the deep, restorative stage essential for memory consolidation and the clearing of metabolic waste.
To analyze the brain’s electrical activity with precision, the researchers applied a mathematical method known as Fitting Oscillations and One Over Frequency (FOOOF). This allowed them to distinguish between rhythmic brain waves and "background noise," essentially functioning like a diagnostic tool for a car engine to determine if the system is idling correctly or running at high, unnecessary speeds. The data confirmed that when the immune system was quieted, the brain was no longer stuck in an "over-active" state during intended rest periods.
A Surprising Discovery About Alzheimer’s Brain Plaques
One of the most counterintuitive findings of the study was the lack of correlation between the severity of amyloid plaque buildup and the intensity of sleep disruption. Dr. Constantino noted that while they expected sleep to deteriorate in direct proportion to the volume of plaques in the brain, they instead observed a "ceiling effect."
"The disruptions in sleep and cortical EEG activity that occur at 6 months, when plaques first emerge, did not worsen by 18 months, despite more than double the amount of plaque burden," Constantino said. This implies that the initial inflammatory trigger is the critical event. Once the microglia are activated, they initiate a set level of sleep disruption that does not necessarily scale with the size or number of plaques. This is a vital clue, suggesting that interventions aimed at curbing the inflammatory response could be effective even in the later stages of the disease, regardless of the amount of amyloid present.
Alzheimer’s Disrupts a Different Type of Sleep Than Normal Aging
The study further clarified how Alzheimer’s specifically targets the architecture of sleep compared to natural aging. While aging is generally associated with a reduction in rapid eye movement (REM) sleep, Alzheimer’s pathology was found to specifically impair NREM sleep. Given that NREM sleep is the period during which the brain performs essential maintenance—including the clearing of toxins and metabolic byproducts—its loss is particularly damaging.
Dr. Macauley emphasized the gravity of this, noting that "restorative sleep is super important for physical repair, learning and memory and washing out the toxins of the day." The disruption of this cycle may be a primary driver of the self-reinforcing nature of Alzheimer’s: the disease causes poor sleep, and poor sleep, in turn, hinders the brain’s ability to clean itself, further accelerating the disease.
Future Directions and Clinical Implications
While the findings in mice are promising, the researchers urge caution, noting that human trials are a necessary next step. Because microglia serve protective functions, depleting them entirely is not a viable long-term treatment strategy for human patients. Instead, the team is investigating ways to "reprogram" or calm these cells using existing medications. They are currently exploring drugs like Metformin, used for diabetes, and the anti-seizure medication Stiripentol, which may alter how microglia use energy and produce inflammatory signals.
Beyond therapeutics, the researchers are optimistic that their findings could lead to more affordable diagnostic tools. Because the study identified specific electrical signatures of Alzheimer’s via EEG, the team believes portable, home-based monitoring could one day serve as an accessible biomarker. Unlike expensive PET scans or invasive lumbar punctures, EEG devices could be used to screen for early signs of the disease in underserved or rural communities, allowing for earlier intervention.
The success of this work, according to Dr. Macauley, is a testament to the collaborative, high-risk environment of her lab at the Sanders-Brown Center on Aging. By challenging the traditional focus on plaques and shifting attention to the brain’s broader immune response, the team has opened a new window into the biology of Alzheimer’s. As the researchers continue to "follow the data," the hope is that calming the brain’s "partying" immune cells could eventually restore not only sleep but the quality of life for those living with the disease.
Research reported in this publication was supported by the National Institute on Aging of the National Institutes of Health under Award Numbers R01AG068330, R01AG093847 and P30AG072946, and by the National Institute of General Medical Sciences of the National Institutes of Health under Award Numbers P30GM127211 and P20GM148326. The work was further supported by the Cure Alzheimer’s Fund and The CART Fund.
